Neuronetics Reports 8% Revenue Growth in Q3 2023, Expects Continued Momentum
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM), a pioneer in the treatment of psychiatric disorders, announced its financial and operating results for the third quarter of 2023 this week. The …
Neuronetics Reports 8% Revenue Growth in Q3 2023, Expects Continued Momentum Read More